News
Gnosis Quatrefolic® earns approval in Australia by TGA
2 September 2016
Gnosis is proud to announce that on August 9th, 2016 Quatrefolic® (Levomefolate glucosamine or also (6S)-5-MTHF glucosamine salt), the biologically active form of the naturally-occurring predominant form of folate, has been approved as permitted ingredient for listed medicines by TGA (Therapeutic Goods Administration) a part of the Australian Government Department of Health, responsible for regulating therapeutic goods including vitamins and minerals.
As part of the Department of Health, the TGA safeguards and enhances the health of the Australian community through effective and timely regulation of therapeutic goods.
Quatrefolic® has been positively evaluated for safety in accordance with current TGA regulations and it is introduced in the list of ‘permissible ingredients’ for use in listed medicines.
“This approval allows our company to immediately begin marketing Quatrefolic® in Australia, “says the East Export Manager Marco Atanassi. “This new success strengthens our international position we are very proud of the work done and to have transformed an idea of the development of an innovative product into a tangible benefit for Australian consumers. This encourages us, even more, to continue on this way to make known the science of well-being and the real benefits deriving from Quatrefolic®.”
Quatrefolic® “the innovactive folate” is structurally analogous to the reduced and active form of folic acid, so Quatrefolic® completely bypasses the conversion steps and delivers a “finished” folate the body can immediately use without any kind of metabolization.
